Drug Trial Radar · NCT05110157
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
442
Actual
Start
Nov 29, 2021
Primary completion
Feb 4, 2025
Study completion Feb 18, 2025
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Nov 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Conditions
- Schizophrenia
Interventions
PlaceboDrug
Oral capsules
ValbenazineDrug
Oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to Week 10Time frame: Baseline to week 10
Locations
87 sites in 4 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Phoenix, Arizona
Neurocrine Clinical Site
Rogers, Arkansas
Neurocrine Clinical Site
Anaheim, California
Neurocrine Clinical Site
Bellflower, California
Neurocrine Clinical Site
Culver City, California
Neurocrine Clinical Site
Garden Grove, California
Neurocrine Clinical Site
Lemon Grove, California
Neurocrine Clinical Site
Long Beach, California
Neurocrine Clinical Site
Oceanside, California
Neurocrine Clinical Site
Pico Rivera, California
Neurocrine Clinical Site
Riverside, California
Neurocrine Clinical Site
San Diego, California
Neurocrine Clinical Site
San Diego, California
Neurocrine Clinical Site
San Jose, California
Neurocrine Clinical Site
Santa Ana, California
Neurocrine Clinical Site
Stanford, California
Neurocrine Clinical Site
Torrance, California
Neurocrine Clinical Site
Aventura, Florida
Neurocrine Clinical Site
Coral Gables, Florida
Neurocrine Clinical Site
Daytona Beach, Florida
Neurocrine Clinical Site
Hialeah, Florida
Neurocrine Clinical Site
Hialeah, Florida
Neurocrine Clinical Site
Hialeah, Florida
Neurocrine Clinical Site
Miami, Florida
Neurocrine Clinical Site
Miami, Florida
Neurocrine Clinical Site
Miami, Florida
Neurocrine Clinical Site
Miami Lakes, Florida
Neurocrine Clinical Site
Okeechobee, Florida
Neurocrine Clinical Site
Tampa, Florida
Neurocrine Clinical Site
West Palm Beach, Florida
Neurocrine Clinical Site
Atlanta, Georgia
Neurocrine Clinical Site
Evanston, Illinois
Neurocrine Clinical Site
Springfield, Illinois
Neurocrine Clinical Site
Grand Rapids, Michigan
Neurocrine Clinical Site
St Louis, Missouri
Neurocrine Clinical Site
St Louis, Missouri
Neurocrine Clinical Site
Lincoln, Nebraska
Neurocrine Clinical Site
Las Vegas, Nevada
Neurocrine Clinical Site
Cedarhurst, New York
Neurocrine Clinical Sites
Glen Oaks, New York
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.